Retatrutide is the drug everyone in the weight-loss corner of the internet is excited about. Tirzepatide is the one people are actually being prescribed. That gap is the whole story here.
What's the actual difference?
Both are peptides — short chains of amino acids, the tiny building blocks that make up protein. Both are made by Eli Lilly. Both work by switching on hormone signals that control hunger and how your body handles energy.
The difference is how many switches they flip. Scientists call these drugs agonists — an agonist is something that turns a receptor on, like a key fitting a lock.
- [Tirzepatide](/peptides/tirzepatide/) is a dual agonist. It fits two locks: GLP-1 (the 'I'm full' signal) and GIP (another gut signal involved in appetite and blood sugar).
- [Retatrutide](/peptides/retatrutide/) is a triple agonist. Same two locks, plus a third — glucagon, a signal that affects how your body burns stored energy.
More targets sounds better. Sometimes it is. It can also mean more ways to cause side effects, which is exactly why regulators want the full trial results before anyone gets a prescription.
The head-to-head
| Factor | Retatrutide | Tirzepatide |
|---|---|---|
| What it is | A triple agonist peptide (GLP-1 + GIP + glucagon), lab code LY3437943 | A dual agonist peptide (GLP-1 + GIP) |
| Approved? | No — investigational, not approved by any major regulator | Yes — FDA-approved (Zepbound for weight, Mounjaro for type 2 diabetes) |
| How it's taken | Injected weekly, inside supervised clinical trials only | Injected weekly, on prescription |
| What trials showed | A Phase 2 trial reported large weight loss; large Phase 3 trials (TRIUMPH programme) are still running | Phase 3 SURMOUNT-1 showed up to about 20.9% average body-weight loss over 72 weeks versus about 3.1% on placebo |
| Main side effects | Mostly gut-related in trials; the full safety picture isn't settled | Mostly gut-related — nausea, vomiting, diarrhoea; carries a boxed warning |
| Banned in sport? | Not a named WADA-prohibited substance, but an unapproved investigational drug is a serious problem for a tested athlete | Not a WADA-prohibited substance, but check current rules with your governing body |
Which one works better?
On paper, retatrutide's Phase 2 numbers were eye-catching — big enough that the trial got a lot of press. Tirzepatide's Phase 3 results are also genuinely strong, and crucially they're *finished*, reviewed, and on a label.
Here's the catch people skip: Phase 2 trials are smaller and shorter than Phase 3 trials, and early results usually look better than the final ones. Comparing an early retatrutide trial to a completed tirzepatide trial isn't a fair fight in either direction. The registrational Phase 3 studies (the TRIUMPH programme) and a huge cardiovascular outcomes trial are still under way. Until those read out, 'retatrutide wins' is a forecast, not a fact.
Is retatrutide approved?
No. Not by the FDA, not by the EMA, not anywhere. It's investigational, which means it's only meant to exist inside supervised clinical trials.
That matters more than it sounds. Anything sold online labelled 'retatrutide' isn't the trial drug. It isn't quality-checked, nobody has verified what's in the vial, and there's no regulator standing behind it. You'd be injecting an unverified substance based on a website's word.
Which is safer?
Tirzepatide, and it isn't close — not because retatrutide has been shown to be dangerous, but because tirzepatide's risks have actually been mapped. It has known side effects, a boxed warning, and a doctor who can watch for problems. Retatrutide's long-term safety profile is still being assembled. 'We don't know yet' is not the same as 'it's fine.'
What's true
- Tirzepatide is FDA-approved and prescription-only; retatrutide is not approved anywhere
- Retatrutide hits three hormone targets, tirzepatide hits two
- Retatrutide's early Phase 2 results reported large weight loss
- Retatrutide's Phase 3 trials are still running, so the full picture isn't in
What's just hype
- 'Retatrutide is proven better than tirzepatide' — no completed head-to-head trial says that
- 'Three targets automatically beats two' — more mechanisms can mean more side effects too
- 'Research-grade retatrutide is the same drug from the trials' — it isn't, and nobody has verified it
Which should you ask a doctor about?
There's only one of these you can actually ask about, and that's tirzepatide. Retatrutide isn't a prescribing option — the only legitimate route to it today is enrolling in a clinical trial, which a doctor can tell you about if one is recruiting near you. That's it. Those are the two real doors.
The honest verdict
Tirzepatide is a finished, approved, well-characterised medicine. Retatrutide is a promising experiment with a bigger mechanism and an unfinished evidence file. Promising is not the same as proven, and 'coming soon' is not the same as available. Watch retatrutide. Don't buy it.
What this does not mean
- This doesn't mean retatrutide is unsafe — it means its safety hasn't been fully established yet, which is a different thing.
- This doesn't mean retatrutide will beat tirzepatide when the Phase 3 results land — early trial numbers often shrink.
- This doesn't mean tirzepatide is right for you — it's an approved medicine with real side effects and a boxed warning.
- This is general information, not medical advice. A doctor decides which medicine, if any, fits your situation.